



UNIVERSITÀ  
DEGLI STUDI  
DELL'AQUILA



DISCAB  
Dipartimento di Scienze  
Cliniche Applicate  
e Biotecnologiche

## CURRICULUM VITAE



PERSONAL INFORMATION	<p>Name and Surname: <b>Maria Esposito</b>          Department: Biotechnological and Applied Clinical Sciences          Address (work): via Vetoio          City: L'Aquila Postal Code: 67100 Nation: Italy          E-mail address (work): <b>maria.esposito3@univaq.it</b></p>
CURRENT POSITION	Associate Professor Dermatology (MED/35 – 06/D4)
<p>EDUCATION OTHER QUALIFICATIONS</p>	<p>2000. Degree in Medicine and Surgery, University of L'Aquila – Italy          2001. Professional Qualification, Medical license number 2956 (ODM L'Aquila)          2003. Diploma of Homeopathy, College of L'Aquila – Italy          2004. Degree of improvement in Dermato-allergology. University of Perugia – Italy          2005. Board certification in Dermatology, University of Rome "Tor Vergata".          2009. Master's degree in Plastic Dermatology, University of Rome "Tor Vergata"</p>
ACADEMIC APPOINTMENTS	<p>2001-2005. Residency in Dermatology. Department of Dermatology University of Rome "Tor Vergata" Clinical dermatology, Dermato-allergology, Dermoscopy, Dermatologic surgery, Clinical research. Dermato-oncology, Dermoscopy.          2011-2012. Research Fellow University of Verona, Italy Clinical research on psoriasis.          2013-2014. Research Fellow University of Verona, Italy Clinical research on psoriasis.          2018-2021. Researcher in Dermatology (MED35-06/D4), Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.          2021-ongoing. Assistant Professor in Dermatology (MED35-06/D4), Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.</p>
CLINIC APPOINTMENTS	<p>1999-2000. Internal doctor. Department of dermato-oncology, University of L'Aquila.          2001-2002. Internal Doctor. Department of Dermatology S.Eugenio Hospital University of Roma "Tor Vergata" Clinical dermatology within an out-patient department devoted to general dermatology, Dermato- oncology, Dermoscopy, Excimer laser phototherapy for psoriasis and vitiligo treatment, Dermato-allergology, Cosmetology.</p>



UNIVERSITÀ  
DEGLI STUDI  
DELL'AQUILA



DISCAB  
Dipartimento di Scienze  
Cliniche Applicate  
e Biotecnologiche



	<p>2001-2005. Residency in Dermatology. Department of Dermatology University of Rome "Tor Vergata" Clinical dermatology, Dermato-allergology, Dermoscopy, Dermatologic surgery, Clinical research. Dermato-oncology, Dermoscopy.</p> <p>2004-2005. Visiting Doctor. Department of Dermatology - Academisch Medisch Centrum University of Amsterdam (AMC-UvA) Clinical Dermatology, Dermato-allergology.</p> <p>2006-2008. Dermatologist, consultant. Department of Dermatology University of Rome "Tor Vergata" Clinical dermatology mainly in a Psoriasis Center of Excellence. Dermato-allergology, Dermoscopy, Clinical Research.</p> <p>2008-2018. Dermatologist, Department of Dermatology University of Rome "Tor Vergata". Part time permanent contract in clinical and research practice, clinical trials.</p> <p>2001-2016. Dermatologist, Local Unit ASL1 Avezzano, Sulmona, L'Aquila. Part time permanent contract for Clinical Dermatology Outpatient Clinics of Celano and Pescina (AQ).</p> <p>2011-2018. Dermatologist, Local Unit of Colferro RMG, Rome, Italy. Part time permanent contract for Clinical Dermatology, Dermoscopy, Dermatologic surgery.</p> <p>2019-ongoing Dermatologist, Asl 1 Abruzzo Avezzano Sulmona L'Aquila. Permanent contract in Dermatology</p>
--	--



UNIVERSITÀ  
DEGLI STUDI  
DELL'AQUILA



DISCAB  
Dipartimento di Scienze  
Cliniche Applicate  
e Biotecnologiche



<p>TEACHING EXPERIENCE</p>	<p>2006-2018. School of Medicine – University of Rome Tor Vergata          2005-2018. Residency in Dermatology and Venereology University of Rome Tor Vergata          2014-2015. Bachelor of Pediatric Dermatology University of Rome Tor Vergata          2017-2018. International Medical School of Tor Vergata          2019-2021. School of Medicine University of L'Aquila          2017-2023. School of Dentistry University of L'Aquila</p>
<p>RESEARCH ACTIVITIES</p>	<p>Clinical Research on psoriasis and atopic dermatitis: epidemiology, clinical and therapeutical aspects of psoriasis and atopic dermatitis, comorbidities, disease experience, psychological aspects and patients quality of life.</p> <p>Efficacy and safety profile of new biologics in adult and pediatric patients in clinical practice, treatment adherence and persistence, "real life" clinical use, predictors of response.</p> <p>Randomized clinical trials phase II and III on new treatment options for inflammatory skin conditions.</p> <p>Participation to national and international collaborative research group.</p> <p>Experimental research on pathogenetic and molecular disease aspects in inflammatory skin disorders.</p>
<p>RESPONSIBILITY IN ACADEMIC ACTIVITIES</p>	<p>Subinvestigator in many randomized clinical trials (&gt;30)</p>



UNIVERSITÀ  
DEGLI STUDI  
DELL'AQUILA



DISCAB  
Dipartimento di Scienze  
Cliniche Applicate  
e Biotecnologiche



<p>EDITORIAL BOARD, EDITORIAL ACTIVITIES, SOCIETY MEMBERSHIP</p>	<p>Reviewer for:</p> <p>Journal of the European Academy of Dermatology and Venereology Dermatologic Therapy Acta DermatoVenereologica Journal of Dermatological Treatment Dermatology Frontiers in Immunology Clinical and Experimental Dermatology</p> <p>Memberships:</p> <p>Società Italiana di Dermatologia Medica, Chirurgica, Estetica e delle Malattie Sessualmente Trasmesse (SIDeMAST) Società Italiana Dermatologia Allergologica e Professionale (SIDAPA) International Dermoscopy Society (IDS) DDI Association (Donne Dermatologhe Italiane) ReDo Association (Reumatologhe Donne)</p>
<p>SCIENTIFIC ACHIEVEMENTS BIBLIOMETRIC INDICATORS</p>	<p><b>Scopus Author ID: 16315368600</b> <a href="http://orcid.org/0000-0002-4773-6993">http://orcid.org/0000-0002-4773-6993</a></p> <p><b>Indicatori Bibliometrici</b> (fonte Scopus) Documents 118, Hirsch (H) Index 24, Citazioni Totali 2171</p>
<p>SELECTED PUBLICATIONS</p>	<p>AUTHOR of 91 publications (articles) on international journals.</p> <p>SELECTION of PUBLICATIONS from the last 10 years:</p> <p>Esposito M et al. Survival rate of antitumour necrosis factor- treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol. 2013 Sep; 169(3): 666-672. ISSN: 0007-0963-doi: 10.1111/bjd.12422.</p> <p>Chimenti MS et al. Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis. Eur J Dermatol. 2013 Apr 1; 23(2): 273-274. ISSN: 1167-1122-doi: 10.1684/ejd.2013.1929.</p> <p>Chimenti MS et al. Remission of psoriatic arthritis after etanercept discontinuation: analysis of patients' clinical characteristics leading to disease relapse. Int J Immunopathol Pharmacol. 2013 Jul-Sep; 26(3): 833-838. ISSN: 0394- 6320-doi: 10.1177/039463201302600333.</p> <p>Di Cesare A et al. Frequency of melanocytic nevi in psoriatic patients is related to treatment and not to disease severity. J Am Acad Dermatol. 2013 Dec; 69(6): 947-953. ISSN: 0190-9622-doi: 10.1016/j.jaad.2013.08.017.</p>



Babino G et al. Entecavir and intermittent etanercept therapy in a patient with concurrent hepatitis B virus infection and psoriasis. *Acta Derm Venereol.* 2013 May; 93(3): 373-4. ISSN: 0001-5555, doi: 10.2340/00015555-1477.

Esposito M et al. Treatment adherence to different etanercept regimens, continuous vs. intermittent, in patients affected by plaque-type psoriasis. *Drug Dev Res.* 2014 Nov; 75 Suppl 1: S31-34. ISSN: 1098-2299-doi: 10.1002/ddr.21190.

Vena GA et al. Some considerations about the importance of alliance between patients and dermatologists in psoriasis. *Clinical Dermatology* 2014; 2: 147-151. ISSN: 2282-4103.

Narcisi A et al. Clinical applications of PPI-TT guidelines on transitioning therapies in the treatment of moderate to severe psoriasis: an expert opinion of central Italy dermatologists. *Clinical Dermatology* 2014; 2: 1-10. ISSN: 2282-4103.

Giunta A et al. Clinical markers predictive of primary inefficacy: a "real life" retrospective study in psoriatic patients treated with etanercept. *Drug Dev Res.* 2014 Nov; 75 Suppl 1: S27-30. ISSN: 1098-2299, doi: 10.1002/ddr.21206.

Ortonne JP et al. Betamethasone valerate dressing is non-inferior to calcipotriol-betamethasone dipropionate ointment in the treatment of patients with mild-to-moderate chronic plaque psoriasis: results of a randomized assessor-blinded multicentre trial. *J Eur Acad Dermatol Venereol.* 2014 Sep; 28(9): 1226-1234, ISSN: 0926-9959-doi: 10.1111/jdv.12270.

Babino G et al. UVA1 Laser in the Treatment of Vitiligo. *Photomed Laser Surg.* 2016 May; 34(5): 200-204. ISSN: 1549-5418-doi: 10.1089/pho.2015.400.

Giunta A et al. Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: a retrospective study. *J Int Med Res.* 2016 Sep; 44(1 suppl): 72-75. ISSN: 0300-0605-doi: 10.1177/0300060515593254.

Esposito M et al. From patients' needs to treatment outcomes in psoriasis: Results from the 'pSORRIDI' experience. *J Int Med Res.* 2016 Sep; 44 (1 suppl): 95-99. ISSN: 0300-0605, doi: 10.1177/0300060515593265.

Babino G, Giunta A, Ruzzetti M, Chimenti MS, Chimenti S, Esposito M. Combination therapy with etanercept in psoriasis: Retrospective analysis of efficacy and safety outcomes from real-life practice. *J Int Med Res.* 2016 Sep; 44 (1 suppl): 100-105. ISSN: 0300-0605, doi: 10.1177/0300060515593260.

Giunta A et al. Spotlight on ixekizumab for the treatment of moderate-to-



severe plaque psoriasis: design, development, and use in therapy. *Drug Des Devel Ther.* 2017 Jun 2; 11: 1643- 1651. doi: 10.2147/DDDT.S92128.

Babino G et al. Morbid obesity and psoriasis: Disease remission after laparoscopic sleeve gastrectomy. *Obes Res Clin Pract.* 2017 May - Jun;11(3):370-372. ISSN: 1871-403X-doi: 10.1016/j.orcp.2017.04.008.

Esposito M et al. Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. *J Eur Acad Dermatol Venereol.* 2017 May; 31(5): 863-869. ISSN: 0926-9959-doi:10.1111/jdv.14145.

Cannizzaro MV et al. Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management. *Psoriasis (Auckl).* 2017 Apr 15;7:35-40.

Babino G et al. Long-term treatment with etanercept monotherapy in a hemodialyzed patient with moderate-to-severe plaque-type psoriasis and psoriatic arthritis. *G Ital Dermatol Venereol.* 2017 Nov 16. doi: 10.23736/S0392-0488.17.05586-9. [Epub ahead of print] PubMed PMID: 29144096.

D'Addabbo P et al. Association between Psoriasis and haplotypes of the IgH 3' Regulatory Region 1. *Gene.* 2018 Aug 30;669:47-51. doi: 10.1016/j.gene.2018.05.090. Epub 2018 May 24. PubMed PMID: 29802990.

Esposito M et al. Efficacy and safety of adalimumab after failure of other anti-TNF $\alpha$  agents for plaque-type psoriasis: clinician behavior in real life clinical practice. *J Dermatolog Treat.* 2018 Nov 6:1-5. doi: 10.1080/09546634.2018.1529382. [Epub ahead of print] PubMed PMID: 30273075.

Chimenti MS et al. Potential Role of Cytochrome c and Trypsin in Psoriasis and Psoriatic Arthritis Pathogenesis: Focus on Resistance to Apoptosis and Oxidative Stress. *Front Immunol.* 2018 Oct 30;9:2363. doi: 10.3389/fimmu.2018.02363. eCollection 2018. Review. PubMed PMID: 30429845; PubMed Central PMCID:PMC6220124.

Chimenti MS et al. Histopathology of the skin in rheumatic diseases. *Reumatismo.* 2018 Oct 3;70(3):187-198. doi: 10.4081/reumatismo.2018.1049.

Del Duca E et al. Rapid, persistent, and simultaneous remission of urticaria and severe atopic dermatitis after treatment with omalizumab. *J Dermatolog Treat.* 2018 Dec 4:1-4. doi:10.1080/09546634.2018.1550246. [Epub ahead of print] PubMed PMID: 30513060.

Manfreda V et al. Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections. *Postgrad Med.* 2019 Jan 31. doi: 10.1080/00325481.2019.1575613. [Epub ahead of print] PubMed





PMID: 30700196.

Giunta A et al. Etanercept biosimilar SB4 in the treatment of plaque-type psoriasis and psoriatic arthritis: a single-centre, observational, retrospective, real-life study. *Br J Dermatol.* 2019 Nov;181(5):1078-1079. doi: 10.1111/bjd.18090. Epub 2019 Aug 5. PMID: 31049938.

Dattola A et al. A case of generalized pustular psoriasis and arthritis treated with ixekizumab. *J Dermatolog Treat.* 2020 Nov;31(7):754-755. doi: 10.1080/09546634.2019.1606395. Epub 2019 May 1. PMID: 30998424.

Chimenti MS, et al. PsA-Disk, a novel visual instrument to evaluate psoriatic arthritis in psoriatic patients: an Italian derma-rheuma multicentre study. *Ther Adv Chronic Dis.* 2019 May 14;10:2040622319847056. doi: 10.1177/2040622319847056. PMID: 31205645; PMCID: PMC6535736.

Gisondi P et al. Consensus on the place in therapy of TNF- $\alpha$  inhibitors in the treatment of patients with chronic plaque psoriasis. *J Eur Acad Dermatol Venereol.* 2020 Sep;34(9):e470-e472. doi: 10.1111/jdv.16380. Epub 2020 May 20. PMID: 32189348.

Cannizzaro MV, et al. Association between psoriasis and periodontitis, and efficacy of anti-TNF- $\alpha$  therapy. *G Ital Dermatol Venereol.* 2020 Aug;155(4):508-511. doi: 10.23736/S0392-0488.18.06045-5. Epub 2018 Oct 22. PMID: 30350557.

De Simone C et al. SIDeMaST "Psoriasis in Women of Childbearing Age" Task Force. Psoriasis and its management in women of childbearing age: tools to increase awareness in dermatologists and patients. *G Ital Dermatol Venereol.* 2020 Aug;155(4):434-440. doi: 10.23736/S0392-0488.20.06748-6. PMID: 33050681.

Scala E et al. Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis. *PLoS One.* 2020 Aug 12;15(8):e0237267. doi: 10.1371/journal.pone.0237267. PMID: 32785291; PMCID: PMC7423114.

Chiricozzi A et al. Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis. *Dermatology.* 2020;236(4):329-335. doi: 10.1159/000507246. Epub 2020 May 5. PMID: 32369808.

Manfreda V et al. Efficacy and safety of ixekizumab in psoriatic arthritis: a retrospective, single-centre, observational study in a real-life clinical setting. *Clin Exp Rheumatol.* 2020 May-Jun;38(3):581-582. Epub 2020 Feb 4. PMID: 32105590.

Esposito M et al. Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series. *Postgrad Med.* 2020 Mar;132(2):172-175. doi: 10.1080/00325481.2020.1712153. Epub 2020 Jan 22. PMID: 31916470.



Esposito M et al. Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. *Expert Rev Clin Immunol.* 2020 Feb;16(2):119-128. doi: 10.1080/1744666X.2020.1713754. Epub 2020 Jan 22. PMID: 31917928.

Esposito M et al. Depressive symptoms and insecure attachment predict disability and quality of life in psoriasis independently from disease severity. *Arch Dermatol Res.* 2020 Aug 10. doi: 10.1007/s00403-020-02116-8. Epub ahead of print. PMID: 32776228.

Hansel K et al. A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic. *J Eur Acad Dermatol Venereol.* 2020 Oct 20. doi: 10.1111/jdv.17003. Epub ahead of print. PMID: 33080112.

Fargnoli MC et al. Dupilumab Italian National Access Program (Dup-INAP group). Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. *J Dermatolog Treat.* 2021 Aug;32(5):507-513. doi: 10.1080/09546634.2019.1682503. Epub 2019 Oct 28. PMID: 31647347.

Fargnoli MC et al. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. *J Dermatolog Treat.* 2020 Jul 3:1-4. doi: 10.1080/09546634.2020.1773379. Epub ahead of print. PMID: 32436765.

Patrino C et al; DADE - Dupilumab for Atopic Dermatitis of the Elderly study group. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. *J Eur Acad Dermatol Venereol.* 2020 Dec 17. doi: 10.1111/jdv.17094. Epub ahead of print. PMID: 33332697.

Fargnoli MC et al. BRILLIANT Working Group. Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience. *J Eur Acad Dermatol Venereol.* 2020 Sep 11. doi: 10.1111/jdv.16931. Epub ahead of print. PMID: 32916767.

Calianno G et al. Ixekizumab improves disease severity, clinical symptoms and quality of life in patients with genital psoriasis: A 24-week real-life experience. *Dermatol Ther.* 2021 Jul;34(4):e14993. doi: 10.1111/dth.14993. Epub 2021 Jun 7. PMID: 34029442.

Esposito M et al. Satisfaction and attitudes toward systemic treatments for psoriasis: A cross-sectional study. *Dermatol Ther.* 2021 May;34(3):e14949. doi: 10.1111/dth.14949. Epub 2021 Mar 25. PMID: 33724607; PMCID: PMC8243966.

Narcisi A et al. Effects of TNF- $\alpha$  inhibition on pre-clinical enthesitis: observational study on 49 psoriatic patients. *J Dermatolog Treat.* 2021 Mar





10:1-4. doi: 10.1080/09546634.2021.1899112. Epub ahead of print. PMID: 33691568.

Troisi A et al. Cutaneous body image in psoriasis: The role of attachment style and alexithymia. *Curr Psychol* (2021). <https://doi.org/10.1007/s12144-021-02032-8>

Stingeni L et al. Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy. *Dermatol Ther*. 2021 Sep;34(5):e15035. doi: 10.1111/dth.15035. Epub 2021 Jun 25. PMID: 34152670.

Chiricozzi A et al. DA-COVID-19 study group. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry. *Allergy*. 2021 Jun;76(6):1813-1824. doi: 10.1111/all.14767. Epub 2021 Mar 9. PMID: 34152613; PMCID: PMC8014537.

De Simone C et al. Risk of infections in psoriasis: assessment and challenges in daily management. *Expert Rev Clin Immunol*. 2021 Nov;17(11):1211-1220. doi: 10.1080/1744666X.2021.1997592. Epub 2021 Nov 1. PMID: 34696673.

Campanati A et al. and collaborators. Correction to: Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study. *Arch Dermatol Res*. 2021 Jul 7. doi: 10.1007/s00403-021-02266-3. Epub ahead of print. Erratum for: *Arch Dermatol Res*. 2021 Jun 7;: PMID: 34235586.

Galluzzo M et al. Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations. *Expert Opin Biol Ther*. 2021 Oct 12:1-10. doi: 10.1080/14712598.2022.1988566. Epub ahead of print. PMID: 34607513.

Esposito M et al. Treatment of severe psoriasis during pregnancy and breastfeeding: A therapeutic challenging case. *Int J Womens Dermatol*. 2021 Aug 27;7(5Part B):832-834. doi: 10.1016/j.ijwd.2021.08.010. PMID: 35028393; PMCID: PMC8714591.

Hansel K et al. Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic. *Clin Exp Dermatol*. 2022 Jan;47(1):165-167. doi: 10.1111/ced.14862. Epub 2021 Aug 24. PMID: 34309892; PMCID: PMC8444687.



Hansel K et al. A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis. *J Eur Acad Dermatol Venereol.* 2022 Feb;36(2):e111-e113. doi: 10.1111/jdv.17656. Epub 2021 Sep 19. PMID: 34510556.

Esposito M et al. Dimethyl Fumarate's Effectiveness and Safety in Psoriasis: A Real-Life Experience During the COVID-19 Pandemic. *Dermatol Ther (Heidelb).* 2022 Feb 1:1–11. doi: 10.1007/s13555-022-00684-3. Epub ahead of print. PMID: 35103934; PMCID: PMC8805130.

Galluzzo M et al. Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year. *Expert Opin Biol Ther.* 2022 Jun 22:1-8. doi: 10.1080/14712598.2022.2090835. Epub ahead of print. PMID: 35708257.

Stingeni L et al. DADA - Dupilumab for Atopic Dermatitis of the Adolescence Study Group. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience. *J Eur Acad Dermatol Venereol.* 2022 Aug;36(8):1292-1299. doi: 10.1111/jdv.18141. Epub 2022 Apr 22. PMID: 35412683; PMCID: PMC9542087.

Perino F et al. Treatment adherence with diclofenac 3% gel among patients with multiple actinic keratoses: an integrated low-intensity intervention program versus standard-of-care. *Ital J Dermatol Venerol.* 2022 Apr;157(2):164-172. doi: 10.23736/S2784-8671.21.07111-5. Epub 2021 Jul 20. PMID: 34282872.

Pellegrini C et al. Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study. *Dermatol Ther (Heidelb).* 2022 Nov;12(11):2613-2626. doi: 10.1007/s13555-022-00797-9. Epub 2022 Sep 28. PMID: 36169883; PMCID: PMC9588094.

Ruscitti P et al. Nail and enthesis assessment in patients with psoriatic disease by high frequency ultrasonography: findings from a single-centre cross-sectional study. *Radiol Med.* 2022 Dec;127(12):1400-1406. doi: 10.1007/s11547-022-01568-4. Epub 2022 Oct 19. PMID: 36260243; PMCID: PMC9747848.

Esposito M et al. Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis. *JAAD Case Rep.* 2022 Nov 5;31:1-5. doi: 10.1016/j.jdcr.2022.10.031. PMID: 36458235; PMCID: PMC9706390.

Duffin KC et al. Treatment of Psoriasis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. *J Rheumatol.* 2023 Jan;50(1):131-143. doi:



UNIVERSITÀ  
DEGLI STUDI  
DELL'AQUILA



DISCAB  
Dipartimento di Scienze  
Cliniche Applicate  
e Biotecnologiche



	<p>10.3899/jrheum.220316. Epub 2022 Nov 1. PMID: 36319014.</p> <p>Gisondi P et al. The Combination of Dupilumab with Other Monoclonal Antibodies. <i>Dermatol Ther (Heidelb)</i>. 2023 Jan;13(1):7-12. doi: 10.1007/s13555-022-00851-6. Epub 2022 Nov 10. PMID: 36355314; PMCID: PMC9823163.</p> <p>Salfi F et al. The role of insomnia in the vulnerability to depressive and anxiety symptoms in atopic dermatitis adult patients. <i>Arch Dermatol Res</i>. 2023 Feb 7. doi: 10.1007/s00403-023-02538-0. Epub ahead of print. PMID: 36749389.</p> <p>Stingeni L et al DADA - Dupilumab for Atopic Dermatitis of the Adolescence study group. A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis. <i>J Eur Acad Dermatol Venereol</i>. 2023 Mar;37(3):e384-e388. doi: 10.1111/jdv.18648. Epub 2022 Oct 18.</p>
--	---

L'AQUILA 19.07.2023